{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:39:05Z","timestamp":1770971945795,"version":"3.50.1"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1097\/01.cco.0000245326.65152.af","type":"journal-article","created":{"date-parts":[[2006,9,21]],"date-time":"2006-09-21T08:12:12Z","timestamp":1158826332000},"page":"584-590","source":"Crossref","is-referenced-by-count":41,"title":["Clofarabine and nelarabine: two new purine nucleoside analogs"],"prefix":"10.1097","volume":"18","author":[{"given":"Varsha","family":"Gandhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Plunkett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20210128","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrd1724","article-title":"Clofarabine","volume":"4","author":"Pui","year":"2005","journal-title":"Nat Rev Drug Discovery"},{"key":"R2-7-20210128","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1021\/jm00080a029","article-title":"Synthesis and biologic activity of 2\u2032-fluoro-2-halo derivatives of 9-\u03b2-D-arabinofuranosyladenine","volume":"35","author":"Montgomery","year":"1992","journal-title":"J Med Chem"},{"key":"R3-7-20210128","first-page":"2386","article-title":"Effects of 2-chloro-9-(2-deoxy-2-fluoro-\u03b2-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5\u2032-trisphosphate","volume":"51","author":"Parker","year":"1991","journal-title":"Cancer Res"},{"key":"R4-7-20210128","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1073\/pnas.89.7.2970","article-title":"Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2\u2032-arabino-fluoro-2\u2032deoxyadenosine","volume":"89","author":"Carson","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R5-7-20210128","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.cgt.7700520","article-title":"Antitumor activity of 2-fluoro-2\u2032-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase","volume":"10","author":"Parker","year":"2003","journal-title":"Cancer Gene Ther"},{"key":"R6-7-20210128","first-page":"2438","article-title":"Biochemical pharmacology and resistance to 2-chloro-2\u2032-arabinofluoro-2\u2032-deoxyadenosine, a novel analogue of cladribine in human leukemic cells","volume":"5","author":"Lotfi","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R7-7-20210128","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0026-895X(24)12176-1","article-title":"Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-\u03b2-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-\u03b2-D-ribofuranosyl)adenine, 2-chloro-9-(2-deoxy-2,2-difluoro-\u03b2-D-ribofuranosyl) adenine in CEM cells","volume":"55","author":"Parker","year":"1999","journal-title":"Mol Pharmacol"},{"key":"R8-7-20210128","first-page":"2847","article-title":"Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-\u03b2-D-arabinofuranosyl)adenine in human lymphoblastoid cells","volume":"55","author":"Xie","year":"1995","journal-title":"Cancer Res"},{"key":"R9-7-20210128","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1158\/1078-0432.CCR-05-2664","article-title":"Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia (CLL): strategy for treatment","volume":"12","author":"Gandhi","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R10-7-20210128","first-page":"3030","article-title":"Deoxynucleotide pool deletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro-\u03b2-D-arabinofuranosyl)adenine","volume":"56","author":"Xie","year":"1996","journal-title":"Cancer Res"},{"key":"R11-7-20210128","first-page":"21","article-title":"Purine and pyrimidine nucleoside analogs","author":"Plunkett","year":"2001"},{"key":"R12-7-20210128","first-page":"3555","article-title":"Effects of deoxyadenosine triphosphate and 9-beta-D-arabinofuranosyl-adenine 5\u2032-triphosphate on human ribonucleotide reductase from Molt-4F cells and the concept of \u2018self-potentiation\u2019","volume":"40","author":"Chang","year":"1980","journal-title":"Cancer Res"},{"key":"R13-7-20210128","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1146\/annurev.biochem.73.011303.073706","article-title":"Cytochrome C-mediated apoptosis","volume":"73","author":"Jiang","year":"2004","journal-title":"Annu Rev Biochem"},{"key":"R14-7-20210128","doi-asserted-by":"crossref","first-page":"9567","DOI":"10.1073\/pnas.95.16.9567","article-title":"Induction of an apoptotic program in cell-free extracts by 2-chloro-2\u2032-deoxyadenosine 5\u2032-triphosphate and cytochrome c","volume":"95","author":"Leoni","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-7-20210128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1074\/jbc.275.1.29","article-title":"Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway","volume":"275","author":"Genini","year":"2000","journal-title":"J Biol Chem"},{"key":"R16-7-20210128","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1182\/blood.V96.10.3537","article-title":"Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria","volume":"96","author":"Genini","year":"2000","journal-title":"Blood"},{"key":"R17-7-20210128","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/15257770008033020","article-title":"Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-\u03b2-D-arabinofuranosyl)adenine, (Cl-F-ara-A)","volume":"19","author":"Waud","year":"2000","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"R18-7-20210128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00280-002-0472-0","article-title":"Mechanisms of the apoptotic activity of Cl-F-araA in a human T-ALL cell line, CCRF-CEM","volume":"50","author":"Takahashi","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"R19-7-20210128","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2003.04.031","article-title":"Phase I clinical and pharmacology study of clofarabine (chloro-2\u2032-fluoro-deoxy-9-beta-D-arabinofuranosyladenine) in patients with solid and hematologic cancers","volume":"21","author":"Kantarjian","year":"2003","journal-title":"J Clin Oncol"},{"key":"R20-7-20210128","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1080\/1042819031000090183","article-title":"Clofarabine-induced acral erythema during the treatment of patients with myelodysplasia and acute leukemia: report of two cases","volume":"44","author":"Chiao","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"R21-7-20210128","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood-2003-03-0925","article-title":"Phase II clinical and pharmacology study of clofarabine in patients with refractory or relapsed acute leukemias","volume":"102","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"R22-7-20210128","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00280-004-0906-y","article-title":"Biochemical modulation of cytarabine triphosphate by clofarabine","volume":"55","author":"Cooper","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"R23-7-20210128","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2004-05-1933","article-title":"Results of a phase 1\u20132 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias","volume":"105","author":"Faderl","year":"2005","journal-title":"Blood"},{"key":"R24-7-20210128","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2005-08-3294","article-title":"Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older","volume":"108","author":"Faderl","year":"2006","journal-title":"Blood"},{"key":"R25-7-20210128","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2003-06-2122","article-title":"Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia","volume":"103","author":"Jeha","year":"2004","journal-title":"Blood"},{"key":"R26-7-20210128","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukaemia","volume":"24","author":"Jeha","year":"2006","journal-title":"J Clin Oncol"},{"key":"R27-7-20210128","first-page":"800S","article-title":"Clofarabine therapy for the treatment of relapsed or refractory pediatric acute leukemias","volume":"22","author":"Jeha","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R28-7-20210128","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1177\/0091270004269236","article-title":"Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia","volume":"44","author":"Bonate","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"R29-7-20210128","first-page":"6335","article-title":"Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias","volume":"9","author":"Gandhi","year":"2003","journal-title":"Clinical Cancer Res"},{"key":"R30-7-20210128","first-page":"3580","article-title":"DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R31-7-20210128","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrd1933","article-title":"Nelarabine","volume":"5","author":"Gandhi","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"R32-7-20210128","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0140-6736(75)91950-9","article-title":"Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity","volume":"1","author":"Giblett","year":"1975","journal-title":"Lancet"},{"key":"R33-7-20210128","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1172\/JCI109058","article-title":"Deoxyguanosine triphosphate as a possible toxic metabolite in the immunodeficiency associated with purine nucleoside phosphorylase deficiency","volume":"61","author":"Cohen","year":"1978","journal-title":"J Clin Invest"},{"key":"R34-7-20210128","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1073\/pnas.75.10.5011","article-title":"Purinogenic immunosufficiency diseases: selective toxicity of deoxyribonucleosides for T cells","volume":"75","author":"Mitchell","year":"1978","journal-title":"Proc Nat Acad Sci U S A"},{"key":"R35-7-20210128","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1073\/pnas.76.4.1998","article-title":"Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function","volume":"76","author":"Gelfand","year":"1979","journal-title":"Proc Nat Acad Sci U S A"},{"key":"R36-7-20210128","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.4049\/jimmunol.125.4.1578","article-title":"The expression of deoxyguanosine toxicity in T lymphocytes at different stages of maturation","volume":"125","author":"Cohen","year":"1980","journal-title":"J Immunol"},{"key":"R37-7-20210128","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/0092-8674(78)90239-8","article-title":"Deoxyguanosine toxicity in mouse T-lymphoma: relationship to purine nucleoside phosphorylase-associated immune dysfunction","volume":"14","author":"Gudas","year":"1978","journal-title":"Cell"},{"key":"R38-7-20210128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1021\/bi00889a004","article-title":"Synthesis of 9-\u03b2-D-arabinofuranosylguanine","volume":"3","author":"Reist","year":"1964","journal-title":"Biochemistry"},{"key":"R39-7-20210128","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1749-6632.1975.tb29251.x","article-title":"Biological activities of some purine arabinosides","volume":"255","author":"Elion","year":"1975","journal-title":"Ann N Y Acad Sci"},{"key":"R40-7-20210128","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0008-6215(00)80531-5","article-title":"An enzymatic synthesis of purine-D-arabinonucleosides","volume":"97","author":"Krenitsky","year":"1981","journal-title":"Carbohydr Res"},{"key":"R41-7-20210128","first-page":"3352","article-title":"2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies","volume":"55","author":"Lambe","year":"1995","journal-title":"Cancer Res"},{"key":"R42-7-20210128","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1200\/JCO.2000.18.5.995","article-title":"The pharmacokinetics of nelarabine and 9-\u03b2-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies","volume":"18","author":"Kisor","year":"2000","journal-title":"J Clin Oncol"},{"key":"R43-7-20210128","first-page":"1817","article-title":"Transport and metabolism of 9-\u03b2-D-arabinofuranosylguanine in a human T-lymphoblastoid cell line: notrobenzylthioinosine-sensitive and -insensitive influx","volume":"50","author":"Prus","year":"1990","journal-title":"Cancer Res"},{"key":"R44-7-20210128","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/0006-2952(89)90500-5","article-title":"Phosphorylation of arabinosyl guanine by a mitochondrial enzyme of bovine liver","volume":"38","author":"Lewis","year":"1989","journal-title":"Biochem Pharmacol"},{"key":"R45-7-20210128","doi-asserted-by":"crossref","first-page":"22847","DOI":"10.1016\/S0021-9258(18)41605-5","article-title":"Substrate specificity of mitochondrial 2\u2032-deoxyguanosine kinase: efficient phosphorylation of 2-chlorodeoxyadenosine","volume":"268","author":"Wang","year":"1993","journal-title":"J Biol Chem"},{"key":"R46-7-20210128","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1016\/S0021-9258(17)33354-9","article-title":"Deoxycytidine kinase from calf thymus: substrate and inhibitor specificity","volume":"251","author":"Krenitsky","year":"1976","journal-title":"J Biol Chem"},{"key":"R47-7-20210128","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.1073\/pnas.74.12.5677","article-title":"Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s)","volume":"74","author":"Carson","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R48-7-20210128","first-page":"3100","article-title":"Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase","volume":"62","author":"Rodriguez","year":"2002","journal-title":"Cancer Res"},{"key":"R49-7-20210128","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood.V61.4.660.660","article-title":"Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells","volume":"61","author":"Cohen","year":"1983","journal-title":"Blood"},{"key":"R50-7-20210128","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1172\/JCI111514","article-title":"Specific cytotoxicity of arabinosyl-guanine toward cultured T-lymphoblasts","volume":"74","author":"Ullman","year":"1984","journal-title":"J Clin Invest"},{"key":"R51-7-20210128","first-page":"1008","article-title":"Metabolism and selective cytotoxicity of 9-\u03b2-arabinofuranosylguanine in human lymphoblasts","volume":"45","author":"Shewach","year":"1985","journal-title":"Cancer Res"},{"key":"R52-7-20210128","first-page":"3646","article-title":"Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts","volume":"45","author":"Verhoef","year":"1985","journal-title":"Cancer Res"},{"key":"R53-7-20210128","first-page":"6498","article-title":"Differential metabolism of 9-\u03b2-D-arabinofuranosylguanine in human leukemic cells","volume":"49","author":"Shewach","year":"1989","journal-title":"Cancer Res"},{"key":"R54-7-20210128","first-page":"2107","article-title":"Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphate in primary human leukemia cells","volume":"3","author":"Rodriguez","year":"1997","journal-title":"Clin Cancer Res"},{"key":"R55-7-20210128","first-page":"4937","article-title":"Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step","volume":"59","author":"Rodriguez","year":"1999","journal-title":"Cancer Res"},{"key":"R56-7-20210128","first-page":"4673","article-title":"Inhibitory effects of 9-\u03b2-D-arabinofuranosylguanine 5\u2032-triphosphate and 9-\u03b2-D-arabinofuranosyladenine 5\u2019-triphosphate on DNA polymerases from murine cells and oncornavirus","volume":"39","author":"Ono","year":"1979","journal-title":"Cancer Res"},{"key":"R57-7-20210128","first-page":"1517","article-title":"Cytotoxicity, metabolism, and mechanisms of action of 2\u2032,2\u2032-difluorodeoxyguanosine in Chinese hamster ovary cells","volume":"55","author":"Gandhi","year":"1995","journal-title":"Cancer Res"},{"key":"R58-7-20210128","first-page":"61","article-title":"Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells","volume":"22","author":"Gandhi","year":"1995","journal-title":"Semin Oncol"},{"key":"R59-7-20210128","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1182\/blood-2003-01-0317","article-title":"Mechanisms for T-cell selective cytotoxicity of arabinosylguanine","volume":"102","author":"Rodriguez","year":"2003","journal-title":"Blood"},{"key":"R60-7-20210128","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2005.03.199","article-title":"Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies","volume":"23","author":"Kurtzberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"R61-7-20210128","first-page":"198a","article-title":"A phase II study of 9-\u03b2-D-arabinosyl-6methoxy-9H-purine (506U78) in patients with relapsed or refractory T-lineage acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): CALGB study 19801","volume":"100","author":"DeAngelo","year":"2002","journal-title":"Blood"},{"key":"R62-7-20210128","doi-asserted-by":"crossref","first-page":"753a","DOI":"10.1182\/blood.V106.11.2681.2681","article-title":"Results of a phase II study of 506U78 (Nelarabine) in refractory indolent B-cell or peripheral T-cell lymphoma","volume":"106","author":"Thompson","year":"2005","journal-title":"Blood"},{"key":"R63-7-20210128","first-page":"639a","article-title":"Phase II study of compound GW506U78 (araG) for patients with indolent B-cell or peripheral T-cell lymphoma previously treated with chemotherapy","volume":"102","author":"Goy","year":"2003","journal-title":"Blood"},{"key":"R64-7-20210128","first-page":"490","article-title":"Compound 506 has activity in mature lymphoid leukemia","volume":"92","author":"O'Brien","year":"1998","journal-title":"Blood"},{"key":"R65-7-20210128","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J Clin Oncol"},{"key":"R66-7-20210128","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.1998.16.11.3607","article-title":"Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response","volume":"16","author":"Gandhi","year":"1998","journal-title":"J Clin Oncol"},{"key":"R67-7-20210128","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1200\/JCO.2001.19.8.2142","article-title":"Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells","volume":"19","author":"Gandhi","year":"2001","journal-title":"J Clin Oncol"},{"key":"R68-7-20210128","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1016\/0006-2952(89)90127-5","article-title":"Interaction of arabinosyl nucleotides in K562 human leukemia cells","volume":"38","author":"Gandhi","year":"1989","journal-title":"Biochem Pharmacol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.cco.0000245326.65152.af","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T23:10:30Z","timestamp":1736550630000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-200611000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.cco.0000245326.65152.af","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}